Renaissance Technologies’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $189K | Sell |
168,392
-12,897
| -7% | -$14.4K | ﹤0.01% | 3184 |
|
|
2025
Q1 | $176K | Buy |
181,289
+22,297
| +14% | +$21.6K | ﹤0.01% | 3102 |
|
|
2024
Q4 | $186K | Buy |
158,992
+84,203
| +113% | +$98.5K | ﹤0.01% | 3187 |
|
|
2024
Q3 | $126K | Buy |
74,789
+3,100
| +4% | +$5.21K | ﹤0.01% | 3219 |
|
|
2024
Q2 | $102K | Buy |
71,689
+1,800
| +3% | +$2.56K | ﹤0.01% | 3181 |
|
|
2024
Q1 | $265K | Buy |
69,889
+7,800
| +13% | +$29.6K | ﹤0.01% | 3132 |
|
|
2023
Q4 | $168K | Buy |
62,089
+3,200
| +5% | +$8.66K | ﹤0.01% | 3183 |
|
|
2023
Q3 | $93K | Buy |
58,889
+2,200
| +4% | +$3.47K | ﹤0.01% | 3265 |
|
|
2023
Q2 | $149K | Buy |
56,689
+2,000
| +4% | +$5.26K | ﹤0.01% | 3361 |
|
|
2023
Q1 | $199K | Buy |
54,689
+500
| +0.9% | +$1.82K | ﹤0.01% | 3285 |
|
|
2022
Q4 | $213K | Sell |
54,189
-4,700
| -8% | -$18.5K | ﹤0.01% | 3387 |
|
|
2022
Q3 | $250K | Sell |
58,889
-5,300
| -8% | -$22.5K | ﹤0.01% | 3281 |
|
|
2022
Q2 | $290K | Buy |
64,189
+500
| +0.8% | +$2.26K | ﹤0.01% | 3474 |
|
|
2022
Q1 | $356K | Sell |
63,689
-4,000
| -6% | -$22.4K | ﹤0.01% | 3389 |
|
|
2021
Q4 | $423K | Sell |
67,689
-20,300
| -23% | -$127K | ﹤0.01% | 3157 |
|
|
2021
Q3 | $869K | Sell |
87,989
-107,717
| -55% | -$1.06M | ﹤0.01% | 2623 |
|
|
2021
Q2 | $1.74M | Sell |
195,706
-94,700
| -33% | -$843K | ﹤0.01% | 2352 |
|
|
2021
Q1 | $3.22M | Buy |
290,406
+11,300
| +4% | +$125K | ﹤0.01% | 1921 |
|
|
2020
Q4 | $2.35M | Sell |
279,106
-19,400
| -6% | -$164K | ﹤0.01% | 2021 |
|
|
2020
Q3 | $1.77M | Buy |
298,506
+26,800
| +10% | +$159K | ﹤0.01% | 2211 |
|
|
2020
Q2 | $1.38M | Buy |
271,706
+176,716
| +186% | +$894K | ﹤0.01% | 2387 |
|
|
2020
Q1 | $445K | Buy |
94,990
+56,600
| +147% | +$265K | ﹤0.01% | 2816 |
|
|
2019
Q4 | $322K | Buy |
38,390
+14,600
| +61% | +$122K | ﹤0.01% | 3052 |
|
|
2019
Q3 | $635K | Buy |
23,790
+3,900
| +20% | +$104K | ﹤0.01% | 2776 |
|
|
2019
Q2 | $428K | Buy |
19,890
+2,201
| +12% | +$47.4K | ﹤0.01% | 3060 |
|
|
2019
Q1 | $219K | Buy |
17,689
+1,423
| +9% | +$17.6K | ﹤0.01% | 3189 |
|
|
2018
Q4 | $101K | Buy |
16,266
+1,687
| +12% | +$10.5K | ﹤0.01% | 3231 |
|
|
2018
Q3 | $157K | Buy |
14,579
+1,984
| +16% | +$21.4K | ﹤0.01% | 3189 |
|
|
2018
Q2 | $165K | Buy |
12,595
+512
| +4% | +$6.71K | ﹤0.01% | 3102 |
|
|
2018
Q1 | $191K | Buy |
12,083
+2,325
| +24% | +$36.8K | ﹤0.01% | 3187 |
|
|
2017
Q4 | $178K | Buy |
9,758
+3,613
| +59% | +$65.9K | ﹤0.01% | 3157 |
|
|
2017
Q3 | $106K | Buy |
6,145
+952
| +18% | +$16.4K | ﹤0.01% | 3075 |
|
|
2017
Q2 | $139K | Buy |
5,193
+1,210
| +30% | +$32.4K | ﹤0.01% | 3045 |
|
|
2017
Q1 | $121K | Buy |
3,983
+1,010
| +34% | +$30.7K | ﹤0.01% | 3061 |
|
|
2016
Q4 | $124K | Buy |
2,973
+865
| +41% | +$36.1K | ﹤0.01% | 3073 |
|
|
2016
Q3 | $146K | Buy |
2,108
+1,505
| +250% | +$104K | ﹤0.01% | 3128 |
|
|
2016
Q2 | $39K | Buy |
+603
| New | +$39K | ﹤0.01% | 3251 |
|